Creating a new imaging agent for better diagnosis and treatment of multiple myeloma
Development and Commercialization of a New Molecularly Targeted Imaging Agent for Multiple Myeloma
This study is testing a new imaging tool to help doctors better find and track multiple myeloma, a type of blood cancer, so that patients can get more accurate diagnoses and tailored treatment plans.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sarya, LLC NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-10933010 on NIH RePORTER |
What this research studies
This research focuses on developing a novel imaging agent specifically designed for the diagnosis, staging, and treatment of multiple myeloma, a common blood cancer. The approach utilizes advanced nuclear medicine techniques, particularly Positron Emission Tomography (PET), to enhance the detection and localization of myeloma cells in the body. By addressing the limitations of existing imaging methods, the study aims to provide a more accurate and sensitive tool for identifying high-risk patients and monitoring treatment responses. Patients may benefit from improved diagnostic accuracy and personalized treatment plans based on the findings from this research.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with multiple myeloma who require accurate staging and monitoring of their condition.
Not a fit: Patients with other types of cancers or those not diagnosed with multiple myeloma may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more accurate diagnoses and better treatment strategies for patients with multiple myeloma.
How similar studies have performed: Previous research has shown promise in developing targeted imaging agents for various cancers, indicating potential success for this novel approach in multiple myeloma.
Where this research is happening
Saint Louis, United States
- Sarya, LLC — Saint Louis, United States (Active)
Researchers
- Principal investigator: Berezin, Mikhail Y. — Sarya, LLC
- Study coordinator: Berezin, Mikhail Y.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.